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Abstract
Background: Recent information on epidemiology and management of post-herpetic neuralgia (PHN), a painful
complication of zoster, is scarce.
Methods: This study was conducted at the Pain Clinic of the Policlinico Tor Vergata, Rome, Italy, on eighty-five
immunocompetent patients with a clinical diagnosis of PHN. At enrollment (time 0, T0), the patients were interviewed
by physicians to obtain demographic data and information about their zoster clinical history and underwent a blood
test for VZV-DNA research. DN4 and SF-12 questionnaires were used to assess the neuropathic nature of pain and the
overall health status, respectively. A one-year follow-up was planned for enrolled cases, who were visited at regular
intervals of at least 3 months.
Results: At T0 all the patients were at least 6 months from the episode of acute zoster and still presented with intense
pain (mean VAS =6.7; mean DN4 = 5.7). Using antivirals within 72 hours from the rash onset was associated to a
significant reduction of pain at T0 (p = 0.006 vs untreated patients). Only 2.6% of patients treated with antivirals during
acute zoster but 18.6% of the untreated ones presented with neuropathic pain at T12 (p =0.007), even though the two
groups were similar at T0. VZV-DNA was found in 5 out of the 50 available blood samples. At the last follow-up visit,
PCS and MCS scores of the PHN patients were found to be recovered over those of the historical age-matched healthy
controls. Undesirable side effects of analgesic therapies were observed in 15.3 to 28.8% of the patients.
Conclusions: Patients who six months after acute zoster still have significant neuropathic pain, have a high probability
of suffering from chronic pain in the subsequent months/years. The initial antiviral treatment has a significant impact
on the pain. Current strategies of analgesic therapy are effective to achieve relief of pain in PHN patients, but they are
burdened with heavy and undesirable side effects.
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Background
Post-herpetic neuralgia (PHN) is the most challenging
and debilitating complication of herpes zoster (HZ) in
immunocompetent hosts. It is characterized by constant
or intermittent burning, itching or aching, with paroxys-
mal or lancinating pain. Other primary characteristic, such
as numbness, tingling and allodynia, also contribute to the
burden of PHN. Pain intensity at the rash onset, age, rash
severity, length of prodromal pain and cranial localization
are more frequently reported as predictors of PHN [1-14].
Several issues concerning diagnosis, prediction and pre-
vention of PHN need, however, to be clarified in view of
recent contributions [15-20].
Despite advances in antiviral therapy during acute HZ
and the more recent introduction of vaccination against
Varicella-zoster virus (VZV) [21], PHN continues to be
a significant clinical problem, with up to 25% of patients
over 60 years developing persistent neuropathic pain
following acute HZ [22-24]. The estimated incidence of
PHN varies with its definition [25-30]. PHN can persist,
in some individuals, for months or years after the HZ
rash has healed, causing suffering for the patient and a
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healthcare providers. Studies vary widely in the reporting
of the duration of persistent pain [31]. Helgason et al. [32]
found that of 13 subjects with persistent pain 12 months
after HZ, 6 still reported pain after 6.3 years. In one study
of patients aged over 65 years, the mean duration of pain
was 3.3 years, and ranged from 3 months to more than
10 years [33]. A few recent prospective studies report on
the persistence of symptoms up to and over 12 months
after HZ onset. In detail, Bouhassira et al. [34] reported
the presence of zoster-related pain in 6% of 1032 patients
12 months after HZ. McKendrick et al. [35] found that of
158 subjects assessed 9 years after HZ, 21% had experi-
enced any pain during the past year; of these, 47% had
been pain-free at the time of discharge from the acute
study. This is the reason why, in the last years, PHN is
emerging as a preferred clinical trial model for chronic
neuropathic pain [36].
The treatment of PHN is presently based on a well
characterized array of drugs and drug associations with
proved efficacy, including tricyclic antidepressants, the
antiepileptic drug gabapentin, pregabalin and opioids,
with some evidence also for topical lidocaine [36]. It re-
mains still unsatisfactory, however, in a substantial propor-
tion of patients, especially those with many comorbidities
and more intense pain at HZ presentation [36].
Acute HZ and consequently PHN particularly afflicts
the immunocompromised and elderly patients, a fact
that has serious implications for health-care delivery in
the context of ageing populations in the developed world
and the worldwide spread of HIV disease. Left untreated,
PHN can become a severe and debilitating condition
affecting all aspects of a patient’s life [37].
The present report focus on the actual impact of diag-
nosis and management of PHN. In detail, the correlations
existing between demographic and clinical characteristics
of patients, the possible utility of VZV-DNA research in
blood, and the efficacy of treatments for pain relief on the
quality of life of PHN patients have been examined.
Methods
Study population and design
Patients with a clinically diagnosed PHN, with pain over
3 VAS for at least 6 months after the onset of acute
zoster, were consecutively enrolled at the Pain Clinic of
the Policlinico Tor Vergata, Rome, Italy, and examined
and treated between January 1, 2009 and November 15,
2010. The study was submitted to and received approval
by the Independent Ethical Committee of the University
of Rome “Tor Vergata”.
Eighty-five immunocompetent patients with PHN gave
written informed consent to be included in the study.
They were interviewed by physicians to obtain demo-
graphic data (i.e. name, age, sex, race/ethnicity), memory
of primary VZV infection and HZ history [presence of a
prodrome (defined as pain before rash onset) and its dur-
ation (range 1 - over 3 days), extent of rash (rash in-
volving 1, 2, or more than two dermatomes) and its
localization, intensity of pain, presence of abnormal
sensations (including tingle and allodynia) and/or itch,
and antiviral therapy]. All data obtained from the inter-
views were recorded in database files.
Participants in the study also were asked to undergo a
blood test for VZV DNA research at the time of enroll-
ment. Blood sampling (5 ml whole blood per patient)
was performed after an overnight fast. Whole blood
samples were collected and DNA was extracted using a
QIAamp DNA blood mini kit (Qiagen Ltd., United King-
dom) according to the manufacturer’s instructions. The
eluted DNA was stored at -20°C. Detection and quantifi-
cation of VZV DNA were performed by using a VZV Q-
PCR Alert kit (Nanogen Advanced Diagnostics, Torino,
Italy). The cut-off of the method was 56 viral copies/ml
and below this level it is able to detect up to 10 copies/
ml of virus, if present.
Different tools were used to quantify and qualify pain in
the enrolled PHN patients. Briefly, the intensity of pain
was evaluated using a visual analog scale (VAS) of 10 cm
in length that was graduated from “0” to “10,” where “0”
represented no pain and “10” the most unbearable pain.
The DN4 questionnaire (which stands for Douleur
Neuropathique en 4 Questions) was used to estimate
the probability of neuropathic pain in our PHN patients.
It consists of 10 items subdivided into two parts: sen-
sory descriptors (seven items) and signs relating to the
sensory examination (three items). The presence of
neuropathic pain was taken to be the dependent variable
and needed to reach a score of at least 4 out 10, while
non-neuropathic pain presented scores of less than 4
out 10. This questionnaire has been well validated in a
number of studies [37-39].
The SF-12 questionnaire was also used in the medical
interviews [40]. It is a generic short form health survey
developed in the USA from the original SF-36, which
produces two summary measures evaluating physical and
mental self-perceived health that are interchangeable with
those from the SF-36. SF-12 has been successfully tested
in nine Western European countries, included Italy, on
large samples of the general population, where it has
proved its brevity, comprehensiveness, reliability, validity
and cross-cultural applicability [40,41].
A one-year follow-up was planned for all the enrolled
cases, who were visited at least every 3 months. Patients
were subjected to drug therapy according to the protocols
currently in use at international level [42,43]. Treatment of
pain was chosen on the basis of the international specific
guidelines [36] paying particular attention to the presence
of eventual comorbidities, drug interactions with drugs
already used in the therapy and potential side effects.
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Statistical analysis
Statistical analysis and data processing were performed
using SPSS software – version 20 for Windows™. All
two-sided statistical tests were performed with a 5%
significance level. Quantitative variables were analysed
by descriptive statistics including mean values, standard
deviation, median, minimum and maximum. Clinical and
demographic characteristics were analysed by Chi-square
test and Analysis of variance (ANOVA).
Results
Study population
The demographic and clinic characteristics of the PHN
patients enrolled in the study are listed in Table 1.
Overall, the group consisted of 85 immunocompetent
individuals (50 female and 35 male) who had received a
clinical diagnosis of HZ at least 6 months before the
enrollment, and whose median age was 74.5 years
(range 47-92) for female and 77 years (range 41-90) for
male. All of them were Caucasian Italians and out-patient
at the Pain Clinic of the Policlinico Tor Vergata, Rome,
Italy.
The information on age, gender, HZ diagnosis and
history, the overall health status and the immune status
were collected by medical interview and visit at the time
of enrollment in the study. Immune status was deter-
mined on the basis of the absence of specific conditions
or treatments, i.e. active cancer, solid organ transplant,
AIDS, chronic corticosteroid use, or other immunosup-
pressive treatments for autoimmune diseases or other
conditions.
Characteristics and correlates of pain
All the patients, in both gender categories, reported to
have had prodromal pain and abnormal sensations in
the days (from 1 to 3) preceding the HZ rash onset. The
rash localization was thoracic in 37 patients and cranial,
cervical or lumbar in 19, 10 and 19 patients, respectively.
The intensity of rash was moderate or severe in the 87%
of patients and mild in the remaining 13%. Only one half
of the patients had received specific antiviral therapy
prescription at the time of the HZ episode.
No statistically significant difference between the two
gender groups in relation to the different parameters
showed in Table 1 was found, with the only exception of
the localization of rash (Chi-square: p < 0.03).
Intense or very intense pain at the time of enrollment
(i.e. time 0, T0) was reported by the majority of the patients
(Figure 1). The patients reporting intense or very intense
pain at T0 were equally distributed in the two gender
categories (p =0.22).
The median duration of pain (time from the rash onset),
which was equal to 9 months (range 6-150) in the total
population sample, was found to be longer for women
than men, i.e. 12 months (range: 6-150) and 6 months
(range: 6-72), respectively ( p = 0.067).
The measures of the intensity and quality of pain at
the time of enrollment and during the follow-up period
are reported in Table 2, where patients with PHN have
been grouped in three main age groups. The neuropathic
nature of pain of participants in the study was assessed
by the positivity of DN4 questionnaire, with scores
greater than 4 in all the patients examined (Table 2). No
difference by age group in relation to the parameter
“pain” was found in our population sample (Table 2).
The use of antiviral therapy (i.e. Aciclovir, Valaciclovir,
Famciclovir or Brivudin), starting within 72 hours from
the rash onset, had been capable of inducing a significant
reduction of pain (VAS average) at the time of enrollment
at the Pain Clinic (T0) (p = 0.006 versus untreated pa-
tients). Further analyses confirmed a significant risk of
having greater pain among patients who had not received
antiviral therapy (Table 3). Moreover, only 2.6 percent of
patients treated with antivirals during acute zoster but
Table 1 Demographic characteristics and herpes zoster
history of patients with post-herpetic neuralgia
Female Male
Number 50 35
Age N (%) N (%)
< 50 2 (4) 1 (3)
51-60 4 (8) 3 (9)
61-70 9 (18) 2 (6)
71-80 18 (36) 13 (27)
>80 16 (32) 16 (46)
Median (range) 74.5 (47-92) 77 (41-90)
Prodromal pain
< 1 day 29 (58) 27 (77)
1-3 days 10 (20) 2 (6)
3 days 11 (22) 6 (17)
Localization of rash
Cranial 9 (18) 10 (29)
Cervical 6 (12) 4 (11)
Thoracic 24 (48) 13 (37)
Lumbar 11 (22) 8 (23)
Severity of rash
Mild 7 (14) 4 (11)
Moderate 22 (44) 14 (40)
Intense 16 (32) 15 (43)
Severe 5 (10) 2 (6)
Therapy
No 23 (46) 20 (57)
Yes 27 (54) 15 (43)
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18.6 percent of the untreated ones presented with neuro-
pathic pain at T12 (p =0.007), even though no difference
among the two groups had been observed at the time of
enrollment (T0).
The efficacy of treatments for pain relief given to the
patients during the overall period of examination, was
demonstrated by a significant reduction of pain (VAS
average) in the patients with PHN at all the times tested
(p <0.001), without significant differences among dif-
ferent age groups (Table 2). However, several patients
reported the occurrence of adverse effects related to
these treatments [i.e. 19/85 (22,4%) at 3 months, 13/85
(15,3%) at 6 months and 24/85 (28,2%) at 12 months].
The main reported side effects were drowsiness, dizzi-
ness, ataxia, mild peripheral edema, and a worsening
of cognitive impairment in elderly patients, in relation
to treatments with the anticonvulsants, gabapentin and
pregabalin; but also anticholinergic side effects such as
sedation, orthostatic hypotension, cognitive decline, and
constipation related to tricyclic antidepressant (TCA), or
nausea, vomiting, dizziness, constipation, drowsiness and
headache related to tramadol.
PCS and MCS scores
The Physical and Mental Health Composite Scale (PCS
and MCS) scores of the patients enrolled in the study
were measured by means of the SF-12 questionnaire. As
expected, they varied as a function of the patients’ age
and were found to be lower in older individuals than in
the younger ones (Table 4).
As shown in the Table 4, the PCS and MCS mean
scores of our patients at the time of enrollment in the
study were found to be sensibly lower than those mea-
sured in a large Italian population sample of healthy indi-
viduals [40], who were used as an historical age-matched
control, thus confirming the devastating effects of PHN
on the patients’quality of life in all the age groups.
At the time of enrollment, PCS mean scores of our pa-
tients were found to be lower in older patients than in
the younger ones, whereas MCS mean scores appeared
Figure 1 Intensity of pain in patients with post-herpetic neuralgia during the follow-up period.
Table 2 Characteristics of pain in patients with post-herpetic neuralgia
Age
55-64 (15 pts) Mean ± SD 65-74 (23 pts) Mean ± SD >75 (47 pts) Mean ± SD P*
VAS at presentation 6.80 (±1.265) 6.83 (±1.230) 6.62 (±1.649) 0.879
VAS at 3 Months 4.80 (±1.1568) 4.00 (±2.412) 3.96 (±1.769) 0.355
VAS at 6 Months 3.67 (±2.690) 3.39 (±2.331) 3.64 (±2.110) 0.933
VAS at 12 Months 2.27 (±1.944) 2.28 (±1.864) 2.85 (±2.167) 0.487
DN4 at presentation 5.80 (±1.265) 5. 48 (±1.163) 5.13 (±1.154) 0.111
DN4 at 12 Months 1.60 (±1.298) 1.35 (±1.434) 1.45 (±1.4) 0.776
*Statistical analysis of differences by Kruskal-Wallis Test.
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to be quite similar (Table 4). The effectiveness of the
treatments used to relieve pain during follow-up was
demonstrated in all the PHN patients studied, through
the observation of an apparent increase in both PCS and
MCS scores, which were found even higher than those
of the historical control (Table 4). Finally, in our study
PCS and MCS mean scores did not differ depending on
the gender of the patients examined (data not shown).
VZV-DNA positivity in peripheral blood of patients with
PHN
Five out of the 50 available blood samples from the total
of 84 PHN patients enrolled in this study were found to
be positive for VZV DNA. Among them were 3 males
(66, 81 and 88 years-old) and 2 females (48 and
75 years-old). Four of them had been affected by thoracic
zoster, whereas the fifth was a 48 y-o woman who has pre-
sented with trigeminal zoster. The demographic and clinic
characteristics of VZV DNA-positive PHN patients are
summarized in the Table 5.
Discussion
This study confirms and extends previous observations
about the natural history of zoster pain in a cohort of
eighty-five consecutive immunocompetent PHN patients,
who were followed prospectively after their admission at
the Pain Clinic, Policlinico Tor Vergata, Rome, Italy, to
receive proper medical therapy for pain relief.
At the time of study entry all the PHN patients were
at least 6 months from the episode of acute zoster and
still presented with intense or very intense pain (VAS >6),
whose neuropathic nature was confirmed by the positivity
of DN4 questionnaire, with scores greater than 4 in all the
patients examined.
Our results clearly indicate that patients who still have
significant neuropathic pain (VAS ≥ 6, DN4 > 4) 6 months
after the acute episode of zoster , have a high probability
of suffering from chronic pain in the subsequent months/
years. This finding is in accordance with data from the
international literature, since, on the basis of recently pub-
lished prospective studies, six months is just emerging as
a reliable time-threshold to discriminate, in the context
of patients with PHN, between those with a more favor-
able or poor prognosis [44]. Consistently, Reda and coll.
have shown that in a population of immunocompetent
patients at high risk of PHN (for both older age and
higher pain intensity), no subjects who were pain free at
6 months showed a recurrence of pain on subsequent
visits [44].
We had shown previously that older age, greater acute
pain intensity, greater rash extent and longer duration of
prodromal pain are independent risk factors in the de-
velopment of post-herpetic neuralgia, by analyzing the
relationship between baseline and 6-month follow-up
data in a sample of 219 Italian immunocompetent her-
pes zoster patients [15]. Even considering the possibility
of recall bias, which is inherent to any study in which
subjects are asked to recall events that may have occurred
months or even years before [16], the results of the
present study clearly confirm previous observation that
severity of disease on acute herpes zoster presentation and
older age are the best indicators of developing post-
herpetic neuralgia.
Table 4 Physical and mental health composite scale scores in patients with post-herpetic neuralgia
55-64 (15 pts) Mean (±SD) 65-74 (23 pts) Mean (±SD) >75 (47 pts) Mean (±SD)
MCS at the first visit 34.86 ± 5.3 34.00 ± 5.8 33.1 ± 8.0
Historical controls* 49.03 ± 10.41 47.79 ± 11.10 45.38 ± 12.09
MCS at 3 Months 45.00 ± 8.4 41.2 ± 7.0 38.9 ± 8.6
MCS at 6 Months 47.00 ± 9.0 45.00 ± 9.1 42.6 ± 10.0
MCS at 12 Months 55.6 ± 3.0 53.3 ± 4.7 51.0 ± 5.6
PCS at the first visit 37.9 ± 7.6 30.7 ± 5.2 29.6 ± 4.9
Historical controls* 48.05 ± 9.52 44.04 ± 10.71 37.85 ± 11.60
PCS at 3 Months 39.3 ± 6.9 37.9 ± 5.4 34.5 ± 6.4
PCS at 6 Months 45.0 ± 7.4 41.5 ± 7.9 36.8 ± 7.8
PCS at 12 Months 53.1 ± 5.9 49.4 ± 5.2 44.0 ± 7.7
*Apolone G et al. QUESTIONARIO SULLO STATO DI SALUTE SF-12 - Versione italiana IRFMN 2005. Copyright 2001 Istituto di Ricerche Farmacologiche Mario
Negri, Milano.
Table 3 Relative risk (RR) of having VAS lower than 5 for
patients with post-herpetic neuralgia, who had been
treated with Antivirals within 72 hours from the rash
onset
p RR (CI 95%)
VAS <5 at T0 NS 0.86 (0.53-0.41)
VAS <5 at T3 NS 0.67 (0.34-1.3)
VAS <5 at T6 0.017 0.42 (0.17-1.0)
VAS <5 at T12 0.05 0.27 (0.04-1.7)
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Our previous studies did not establish female gender
as a predictor of post-herpetic neuralgia [15]. Similarly,
Dworkin and Schmader [45] did not find sex differences
to be associated with the various aspect of herpes zoster,
with the only exception being the intensity of acute pain
which is higher in women than in men, as also confirmed
by us previously [46]. It is conceivable that the earlier
reported association between gender and long-term pain
may have been a consequence of the fact that more
women were in the higher age strata [47]. Also, among
the 85 PHN subjects, who have been enrolled in the
present study, there were more females than males as in-
deed is observed in the general population [15].
It is a matter of fact, however, that the median dur-
ation of pain before going to the pain clinic, which in
the present study was equal to 9 months (range 6-150)
in the total population sample, was found to be longer
for women than men, i.e. 12 months (range: 6-150) and
6 months (range: 6-72), respectively, approaching the
statistical significance and raising the question of gender
differences with regard to the PHN.
Interestingly, a recent study shows that the incidence
of CNS disease caused by alphaherpesvirus (VZV, HSV-1
and HSV-2) is associated with gender and its influence
varies over the lifetime [48]. Starting from the observation
that the susceptibility to and the severity of several viral
infections is higher in men than in women [48], the
Authors suggest that heightened antiviral responses typical
of female gender, although effective for rapid virus
clearance, can result in chronic/inflammatory patholo-
gies, if excessively high or prolonged [49]. Their sugges-
tion is based on the finding that compared to females,
peripheral blood mononuclear cells from males produce
lower amounts of IFN-α and higher amounts of the im-
munosuppressive cytokine IL-10 following stimulation
with different toll-like receptors (TLRs) ligands or viruses,
and some of these differences related with plasma levels of
sex hormones [49]. Should this hypothesis be tested in a
sufficiently large sample of patients with PHN, it could be
evidence in favor of those who argue that protracted pain
after HZ occurs either as a result of a severe neuronal
injury at the time of zoster onset and/or a failure to re-
cover normal neuronal function following an abnormal
host’s inflammatory response [44,50,51].
Although current guidelines recommend antiviral treat-
ment within 72 hours from the rash onset in individuals
aged over 50 years, with the aim of reducing the incidence
and duration of PHN, only around one half of our PHN
patients had received appropriate treatment. However,
when considering that, as reported recently, 78.4% of
zoster patients receive antiviral therapy in Italy [52], the
herein reported results confirm that antiviral therapy of
acute zoster is absolutely effective although not com-
pletely satisfactory in the prevention of PHN. Consistently,
the group of our PHN patients who had been treated with
antivirals during acute zoster, showed a reduced risk of
higher pain during the follow-up and a significantly lower
percentage of individuals with residual neuropathic pain
at T12, compared with the untreated groups of PHN pa-
tients. Although the correlation is based, at least in part,
on anamnestic data, which represents a possible bias, its
meaning is quite clear. These findings potentially suggest
less nerve damage [53], but can also be explained by the
variability of clinical response and even more importantly
by the efficacy of pain treatments. Therefore, these results
need further confirmation on larger, prospective and ran-
domized studies.
Quality of life is dramatically reduced in patients with
long-lasting PHN. Consistently, PCS and MCS scores of
our patients at the time of enrollment in the study were
found to be sharply lower than those of a large Italian
population sample of healthy individuals, who were used
as an historical age-matched control. As expected, not
only the MCS scores but even more the PCS scores of
our patients varied as a function of the patients’ age and
were found to be lower in older individuals than in the
younger ones. Also, it has to be emphasized that treat-
ments used for pain relief seemed to have worked in all
the patients enrolled in the study regardless of age
groups or gender. This fact outlines the importance of a
systematic and specialized approach to the problem of
chronic pain in PHN patients. The nature of neuropathic











Prodromal pain < 1 day < 1 day < 1 day < 1 day < 1 day
Rash onset 6 months 80 months 7 months 60 months 36 months
Rash localization Thoracic Thoracic Thoracic Trigeminal Thoracic
Rash intensity Severe Intense Moderate Moderate Moderate
Antiviral therapy No No Yes No No
VAS (T0) 8 6 7 8 5
DN4 (T0) 7 8 4 4 4
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pain in PHN is variable, so that it may be described as
continuous or paroxysmal, evoked or spontaneous, burn-
ing or lancinating, and be associated with a range of other
sensory abnormalities in the skin [54]. This variability in
symptoms could imply that a variety of different pain
mechanisms might be operating in different patients with
PHN or in the same patient at different time points [54].
Therefore, treatment protocols should be optimised for
individual patients on the basis of symptoms or even
mechanisms [36]. Actually, no substantial evidence base
exists to relate specific sets of symptoms or signs to the
efficacy of specific drugs, and no simple validated methods
exist to determine which neuropathic pain mechanism(s)
may be operating in a single patient. Moreover, no single
treatment has been shown to be completely effective for
all sufferers of PHN, and combinations of analgesic drugs
are usually required to achieve at least a partial relief of
pain [36]. Tricyclic antidepressants, gabapentinoids and
strong opioids are effective but are also associated with
systemic adverse events that may limit their use in many
patients, most notably those with significant medical co-
morbidities or advanced age [55]. Also, compliance of pa-
tients with treatment is an important factor in the clinical
effectiveness of therapies, and a major factor governing
compliance is withdrawal due to side effects (major harm).
Finally, our results do not allow us to confirm a clear
relationship between the positivity/persistence of VZV
viremia and PHN, since only 5 out of the 50 available
blood samples from the PHN patients in the study were
found positive for VZV DNA search. Other reports show
comparatively higher percentages of VZV DNA-positivity
in blood or saliva of patients affected by HZ and/or PHN
[18,56]. It is worth mentioning, however, that searching
for VZV DNA in blood of our PHN patients was per-
formed only once in the course of the study. A possible
reason for the discrepancy of the PCR results may be also
related to the sensitivity of the different methods for
VZV-DNA detection in blood. For VZV, as well as for
other herpes viruses, a variety of methods, techniques
and protocols have been used to measure viral load at
many institutions [57]. However, because each institution
monitors VZV load with its own “homebrew” system, de-
tection techniques and viral load estimation values have
not been standardized and results vary between different
laboratories [56,57].
It seems that up to date, in spite of the large body of
evidence available in the literature, there is still a need
to gain new insights on the mechanism/s underlying
PHN pathogenesis, which at present remains not fully
elucidated. In detail, whether PHN pathogenesis is due
to persistent productive virus infection in ganglia or to
neuronal cell damage (i.e. altered excitability of ganglionic
or even spinal cord neurons), is still controversial [58-67].
The possibility that protracted pain after zoster occurs
either as a result of severe neuronal injury at the time of
zoster onset or a failure to recover normal neuronal func-
tion [29,30] is sustained by the very recent demonstration
that there is only a modest recovery of sensory function
and no anatomic recovery despite pain resolution in late
follow-up of a group of PHN patients [44]. Further studies
aimed at deepening our knowledge on PHN pathogenesis
are currently in progress in our laboratories.
Conclusions
We report that patients who still have significant neuro-
pathic pain six months after acute zoster present a high
probability of suffering from chronic pain in the subsequent
months/years. Antiviral therapy used within 72 hours from
the rash onset reduces the risk of higher VAS in the
follow-up. Current strategies of analgesic therapy are ef-
fective to achieve relief of pain in PHN patients, but they
are burdened with heavy and undesirable side effects.
PHN represents a major public health problem. In spite of
the large body of evidence available in the literature, there
is still a need to gain new insights on chronic pain, its bur-
den and the efficacy of available treatments.
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